A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. [electronic resource]
Producer: 20180521Description: 1024-e89 p. digitalISSN:- 1549-490X
- Acneiform Eruptions -- epidemiology
- Administration, Oral
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Asthenia -- epidemiology
- Azetidines -- pharmacology
- Colorectal Neoplasms -- drug therapy
- Dose-Response Relationship, Drug
- Drug Eruptions -- epidemiology
- ErbB Receptors -- antagonists & inhibitors
- Female
- Humans
- Hypokalemia -- epidemiology
- Immunoglobulin G -- pharmacology
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- Male
- Middle Aged
- Neoplasm Staging
- Piperidines -- pharmacology
- Prospective Studies
- Proto-Oncogene Proteins p21(ras) -- genetics
- Receptor, ErbB-3 -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.